Next Article in Journal
Bovine Lactoferrin-Induced CCL1 Expression Involves Distinct Receptors in Monocyte-Derived Dendritic Cells and Their Monocyte Precursors
Next Article in Special Issue
Botulinum toxin A for the Treatment of Overactive Bladder
Previous Article in Journal
Toxins: State of Journal Report, 2016
Article Menu

Export Article

Open AccessArticle
Toxins 2015, 7(12), 5462-5471; doi:10.3390/toxins7124896

Does Reduction of Number of Intradetrusor Injection Sites of aboBoNTA (Dysport®) Impact Efficacy and Safety in a Rat Model of Neurogenic Detrusor Overactivity?

1
Pelvipharm, 2 avenue de la source de la Bièvre, Bâtiment Simone Veil, Université de Versailles-Saint-Quentin-en-Yvelines, Montigny-le-Bretonneux 78180, France
2
Unité de Formation et de Recherche des Sciences de la Santé, Université de Versailles-Saint-Quentin-en-Yvelines, Institut National de la Santé Et de la Recherche Médicale U1179, Montigny-le-Bretonneux 78180, France
3
IPSEN Innovation, 5 avenue du Canada, Les Ulis 91140, France
4
Assistance Publique-Hôpitaux de Paris, Neuro-Uro-Andrology, Raymond Poincaré Hospital, Department of Physical Medicine and Rehabilitation, Garches 92380, France
*
Author to whom correspondence should be addressed.
Academic Editor: Hann-Chorng Kuo
Received: 9 October 2015 / Revised: 3 December 2015 / Accepted: 10 December 2015 / Published: 17 December 2015
(This article belongs to the Special Issue Botulinum Toxin A on Lower Urinary Tract Dysfunction)
View Full-Text   |   Download PDF [1146 KB, uploaded 17 December 2015]   |  

Abstract

Intradetrusor injections of Botulinum toxin A—currently onabotulinumtoxinA—is registered as a second-line treatment to treat neurogenic detrusor overactivity (NDO). The common clinical practice is 30 × 1 mL injections in the detrusor; however, protocols remain variable and standardization is warranted. The effect of reducing the number of injection sites of Dysport® abobotulinumtoxinA (aboBoNTA) was assessed in the spinal cord-injured rat (SCI). Nineteen days post-spinalization, female rats received intradetrusor injections of saline or aboBoNTA 22.5 U distributed among four or eight sites. Two days after injection, continuous cystometry was performed in conscious rats. Efficacy of aboBoNTA 22.5 U was assessed versus aggregated saline groups on clinically-relevant parameters: maximal pressure, bladder capacity, compliance, voiding efficiency, as well as amplitude, frequency, and volume threshold for nonvoiding contractions (NVC). AboBoNTA 22.5 U significantly decreased maximal pressure, without affecting voiding efficiency. Injected in four sites, aboBoNTA significantly increased bladder capacity and compliance while only the latter when in eight sites. AboBoNTA significantly reduced NVC frequency and amplitude. This preclinical investigation showed similar inhibiting effects of aboBoNTA despite the number of sites reduction. Further studies are warranted to optimize dosing schemes to improve the risk-benefit ratio of BoNTA-based treatment modalities for NDO and further idiopathic overactive bladder. View Full-Text
Keywords: abobotulinumtoxinA; injection procedure; injection site number; neurogenic detrusor overactivity; spinal-cord injury abobotulinumtoxinA; injection procedure; injection site number; neurogenic detrusor overactivity; spinal-cord injury
Figures

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Huynh Le Maux, A.; Pignol, B.; Behr-Roussel, D.; Blachon, J.-L.; Chabrier, P.-E.; Compagnie, S.; Picaut, P.; Bernabé, J.; Giuliano, F.; Denys, P. Does Reduction of Number of Intradetrusor Injection Sites of aboBoNTA (Dysport®) Impact Efficacy and Safety in a Rat Model of Neurogenic Detrusor Overactivity? Toxins 2015, 7, 5462-5471.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Toxins EISSN 2072-6651 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top